NEW YORK, Nov. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides. Although a relatively underdeveloped market at present the injectable drug delivery has a substantial pipeline, and with significant strides in development of nanotechnology and DNA drug delivery over the past 5 years, injectable drug delivery is set to be an important component of the future pharmaceuitical landscape.
This report evaluates the current and evolving technologies used for injectable drug delivery, the key therapuetic areas, the barriers and driving forces for this market, the competitive landscape is analysed according the technology type, and key pipeline companies and products are examined. Leading companies in the injectable drug delivery market are also profiled.
Key Features of this report• Overview of injectable drug delivery technologies and their mechanisms.
• Profile of key therapeutic areas for injectable drug delivery including, acromegaly, diabetes, hepatitis C, HIV, oncology, pain, schizophrenia and substance abuse.
• Analysis of key therapeutic areas will include incidence rates, current injectable treatments and future directions for injectable drug delivery in this area.
• Market drivers for injectable drug delivery will be examined including patient adherence and the reduction of toxicity, as well as how advances in nanotechnology and genomics are driving the market.
• The threat from alternative delivery methods will also be examined as well as current regulatory issues.
Scope of this report• Understand current market dynamics and drivers for injectable drug delivery.
• Understand the injectable drug delivery market in terms of segment sizes as well as market shares.
• Understand the key technologies used for injectable drug delivery and their mechanisms.
• Evaluate major market participants, their technologies, pipeline and weaknesses and strengths.
• Develop an understand of the developmental pipeline for injectable drug delivery and key innovations driving the future direction of the market.
Key Market Issues• Injectable drug delivery has a significant potential to drive the future market, however, at present only a few key products have enjoyed significant market success.
• Nanotechnology and DNA drug delivery are set to shape future markets significantly, both have a very strong pipeline, but DNA delivery has yet to have any proven market success.
• Therapy areas where adherence is a significant problem area present a major area of opportunity for injectable delivery. Current key market successes such as Risperdal Consta demonstrate the role that injectable delivery has to play in overcoming adherence problems, and future potential in areas such as mental health, diabetes and HIV are set to ensure the continued success of injectable delivery.
Key findings from this report• The injectable drug delivery market holds great potential but is still in its infancy. Successes so far are dominated by just a few products.
• The injectable delivery pipeline is very strong and disproportionate at present to the current market, suggesting it may have a much more significant influence on the future market with the increased use of proteins and peptides.
• DNA technology is yet to prove successful, despite significant investment and research there has been only 1 successful marketed product, which has not achieved great market success.
• Nanotechnology holds the greatest potential for success in the near future. Current products enjoy some increasing success and there is a strong pipeline with products in high revenue therapy areas.
• Although sustained release products will continue to be used, there is little development in this field with a greater move towards nanotechnology and DNA drug delivery.
Key questions answered• What are the key technologies used to enable drug delivery using injections?
• What are the mechanisms of key technologies?
• What are the key therapy areas for injectable drug delivery? What is their incidence?
• What products are used at present for key therapy areas and how will injectable delivery shape the future treatment of these therapy areas?
• What is the size of the current injectable delivery market and what is the share of the key products and market participants?
Companies mentionedAlkermes, Bioject, Debiopharm, Elan Drug Technologies, Enzon, Ferring International, Nektar, QLT
Table of ContentsInnovations in injectables
Executive Summary 10
Key therapeutic areas for injectables 11
Market drivers and barriers 13
Competitive landscape 14
Company profiles of key players 15
Chapter 1 Introduction 20
Types of injectable drug delivery 23
Controlled release 23
Mechanisms of controlled release 24
Drivers and restraints for controlled release formulations 25
Needle free delivery 26
Mechanisms of needle free delivery 27
Drivers and restraints for needle free technologies 29
Nanotechnology and microspheres 30
Mechanisms of nanotechnology drug delivery 31
Drivers and restraints – nanotechnology 35
Gene based drug systems 35
Electrical techniques 37
Vector assisted delivery 37
Drivers and restraints – gene based drug systems 38
Chapter 2 Key areas for injectable drug delivery 42
Background to therapeutic area 44
Current treatments 45
Looking forward 46
Background to therapeutic area 46
Type 1 diabetes 47
Type 2 diabetes 47
Current treatments 48
Looking forward 49
Hepatitis C 50
Background to therapeutic area 50
Current treatments 51
Looking forward 51
Background to therapeutic area 52
Current treatments 53
Looking forward 53
Background to therapeutic area 54
Current treatments 55
Looking forward 56
Schizophrenia and substance abuse 58
Background to therapeutic areas 58
Current treatments 59
Substance abuse 59
Looking forward 60
Chapter 3 Market drivers and resistors 62
Key drivers 63
Improving patient compliance 63
Reducing toxicity 65
Advances in nanotechnology 66
Advances in genomics 69
The threat from alternative delivery methods 71
Oral delivery of proteins and peptides 71
Pulmonary delivery of proteins and peptides 72
Transdermal delivery of proteins and peptides 73
Regulatory issues 75
Nanotechnology regulation 75
Gene therapy regulation 76
Regulations impacting needle free injections 77
Chapter 4 Competitive landscape 80
Overall injectables market 81
Sustained release 81
Marketed products and market share 81
Emerging technologies 84
Marketed products and market share 88
Emerging technologies 91
Other novel injectable formulations 96
Marketed products and market share 96
Emerging technologies 96
Chapter 5 Company profiles of key players 104
Technology platforms 106
Product pipeline 107
SWOT analysis 109
Technology platforms 110
Product pipeline 110
SWOT analysis 112
Debiopharm group 113
Technology platforms 113
Product pipeline 114
SWOT analysis 117
Technology platforms 118
Product pipeline 119
SWOT analysis 121
Enzon pharmaceuticals 121
Technology platforms 122
SWOT analysis 125
Technology platforms 126
SWOT analysis 127
Nektar therapeutics 127
Technology platforms 128
SWOT analysis of Nektar 134
Technology platforms 135
SWOT analysis for QLT 136
Chapter 6 Conclusions 138
List of FiguresFigure 1.1: Liquid jet injection technology vs. needled injection 28
Figure 1.2: Glide SDI solid dosing needle free delivery 28
Figure 1.3: Liposomal drug delivery 33
Figure 2.4: Distribution of Global Cancer Burden by WHO Region (2008) 55
Figure 4.5: Sustained release injectable market share analysis of leading products worldwide 2008 82
Figure 4.6: Sustained release injectable market share analysis of leading drug delivery companies 2008 84
Figure 4.7: Nanotechnology injectable market share analysis of leading products worldwide 2008 89
Figure 4.8: Nanotechnology injectable market share analysis of leading drug delivery companies 2008 90
Figure 5.9: Medisorb microsphere technology 107
Figure 5.10: Alkermes product pipeline, Dec, 2009 108
Figure 5.11: SWOT analysis of Alkermes 109
Figure 5.12: Bioject pipeline 111
Figure 5.13: SWOT analysis of Bioject 112
Figure 5.14: Debiopharma pipeline 116
Figure 5.15: SWOT analysis of Debiopharm 117
Figure 5.16: Elan's product pipeline 120
Figure 5.17: SWOT analysis of Elan 121
Figure 5.18: Enzon's product pipeline 123
Figure 5.19: SWOT analysis of Enzon 125
Figure 5.20: SWOT analysis of Ferring 127
Figure 5.21: Nektar's product profile 133
Figure 5.22: SWOT analysis of Nektar 134
Figure 5.23: SWOT analysis of QLT 136
List of TablesTable 1.1: Drivers and barriers for the use of injections in delivering drugs 22
Table 1.2: The role of innovative drug delivery technologies 23
Table 1.3: Types of microspheres 34
Table 1.4: DNA delivery methods 37
Table 2.5: Acromegaly – key injectable therapies 46
Table 2.6: Estimated numbers of people with diabetes by region for 2000 and 2030 and summary of population changes 48
Table 2.7: Key injectable therapies for Diabetes 50
Table 2.8: Estimated incidence of hepatitis C by WHO region 51
Table 2.9: Hepatitis C key injectable therapies 51
Table 2.10: Regional HIV Statistics 2001 and 2007 52
Table 3.11: Notable drug delivery companies / platforms - nanotechnology 68
Table 3.12: Notable drug delivery companies / platforms - genomics 70
Table 4.13: Worldwide injectables market 81
Table 4.14: Sustained release injectable market share & CAGR analysis of leading products worldwide 2008 82
Table 4.15: Sustained release injectable drug delivery companies market share analysis worldwide
Table 4.16: Patent expiry leading sustained release compounds (still in patent) 84
Table 4.17: Selected emerging technologies in sustained release 86
Table 4.18: Nanotechnology injectable market share & CAGR analysis of leading products worldwide 2008 89
Table 4.19: Nanotechnology injectable drug delivery companies market share analysis worldwide 2008 90
Table 4.20: Patent expiries of leading nanotechnology compounds (still in patent) 90
Table 4.21: Selected emerging technologies in nanotechnology 91
Table 4.22: Selected emerging technologies in nanotechnology 97
Table 5.23: Alkermes in brief 106
Table 5.24: Bioject in brief 109
Table 5.25: Debiopharm group in brief 113
Table 5.26: Elan in brief 117
Table 5.27: Enzon in brief 121
Table 5.28: Ferring in brief 125
Table 5.29: Nektar in brief 127
Table 5.30: QLT in brief 134
Copyright©2010 PR Newswire.
All rights reserved